Clinical trials: Primary Glioblastoma
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor…
- Conditions
- Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
- Trial name
- NCT04094610
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 75 people
- Sponsor
- Turning Point Therapeutics, Inc.
Brain and Central Nervous System Tumors
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00098761
- Testing
- laromustine
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioma, Glioblastoma
Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma
This phase II trial studies the side effects of solriamfetol in improving sleep in patients with grade II-IV glioma. Solriamfetol is a wakefulness-promoting drug.
- Trial name
- JAZZ (NCT03868943)
- Testing
- Soliramfetol
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give…
- Trial name
- NCT00008008
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Grade II Glioma, Grade III Glioma
Implantable Microdevice In Primary Brain Tumors
This pilot study will assess the safety and feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in malignant brain tumors.
- Conditions
- Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma
- Trial name
- NCT04135807
- Testing
- Microdevice
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Oliver Jonas
High Grade Glioma, BRAF V600E
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
- Conditions
- High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma
- Trial name
- BRAF (NCT03973918)
- Testing
- Encorafenib, Binimetinib, Research Bloods
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain (Nervous System) Cancers, Glioblastoma
Pharmacoscopy for Patients With Refractory Primary Brain Tumors
Advanced technology of ex vivo drug profiling referred to as pharmacoscopy may allow to identify novel drugs for the treatment of glioblastoma and other refractory brain tumors at an individual patient level.
- Conditions
- Brain (Nervous System) Cancers, Glioblastoma, Glioma, Ependymoma
- Trial name
- EViDENCE-BT (NCT06804655)
- Testing
- Pharmacoscopy 1.0
- Where
- 3 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Glioblastoma, Anaplastic Astrocytoma
Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly
The study aims to optimize the treatment of elderly subjects (> 65) with anaplastic astrocytoma and glioblastoma. Current treatment policies tend to be no more than palliative.
- Trial name
- Methusalem (NCT01502241)
- Testing
- Temozolomide, Radiotherapy of the partial brain.
- Where
- 23 sites in Germany, Switzerland
- Volunteers
- 412 people
- Sponsor
- Heidelberg University
Glioma Tumor Recurrence, Radiation Necrosis
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
This study will examine the use of a variation of standard magnetic resonance imaging (MRI) called diffusion tensor MRI (DT-MRI) for distinguishing injured brain tissue due to radiation therapy (radiation necrosis) from the…
- Conditions
- Glioma Tumor Recurrence, Radiation Necrosis, Primary Brain Tumor
- Trial name
- NCT00285324
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
End of Life, Advanced Cancer
Engagement of Patients With Advanced Cancer
The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced…
- Conditions
- End of Life, Advanced Cancer, Lung Neoplasm, Gastric Cancer
- Trial name
- EPAC (NCT02966509)
- Testing
- EPAC
- Volunteers
- 213 people
- Sponsor
- Stanford University
Brain Tumor, Recurrent, Glioblastoma Multiforme
A Phase I/II Study of the Photon Radiosurgery System
The standard treatment for children with brain tumors is surgical removal of the tumor followed by radiation to the brain and chemotherapy (medicines) given to shrink any remaining tumor or to prevent tumor from growing back.
- Trial name
- NCT00179907
- Testing
- Photon Radiosurgery System (Intrabeam)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Brain and Central Nervous System Tumors
Biological Therapy in Treating Patients With Primary or Advanced Glioma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or…
- Trial name
- NCT00003067
- Testing
- aldesleukin, lymphokine-activated killer cells
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Malignant Brain Tumors
Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
RATIONALE: Current therapies for adults with primary malignant brain tumors that have not responded to standard therapy provide very limited benefit to the patient.
- Trial name
- NCT00003475
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Glioblastoma Multiforme
Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme
The main purpose of this study is the evaluation of concomitant association of ultrafractionated irradiation and Temodal® in patients with inoperable primary glioblastoma multiforme; study of tolerance and objective response…
- Trial name
- TEMOFRAC (NCT03310372)
- Testing
- Ultrafractionated brain irradiation, Temozolomide
- Volunteers
- 46 people
- Sponsor
- Central Hospital, Nancy, France
Brain and Central Nervous System Tumors, Radiation Toxicity
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such as thinking, attention, concentration, and memory) and may improve quality of life in patients who have undergone radiation therapy to…
- Trial name
- NCT00070161
- Testing
- EGb761, donepezil hydrochloride, cognitive assessment
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Wake Forest University Health Sciences
Glioblastoma Multiforme, Brain Tumor, Adult: Glioblastoma
Multimodality MRI and Liquid Biopsy in GBM
Patients with a new diagnosis of high-grade glioma based on MRI, who are considered surgical candidates determined by neurosurgeons or patients with recurrent glioblastoma with the initial diagnosis of glioblastoma (histologic or…
- Conditions
- Glioblastoma Multiforme, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Recurrent, Brain Tumor, Primary
- Trial name
- NCT04776980
- Testing
- Post Feraheme Infusion MRI
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as gimatecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087061
- Testing
- gimatecan
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas
RATIONALE: Diagnostic procedures, such as positron emission tomography using fluorothymidine F 18, may be effective in finding recurrent disease in patients with gliomas.
- Trial name
- NCT00276770
- Testing
- fluorine F 18 fluorothymidine, positron emission tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Glioblastoma
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Objective: To determine activity of combo of Irinotecan + Temozolomide To further characterize any toxicity associated w combo of Irinotecan + Temozolomide
- Trial name
- NCT00616005
- Testing
- Temodar and Irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Duke University